Pancreatic Cancer Research

ResearcherMount Sinai HospitalActive in the last 2 years

Ayelet Borgida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8058-8953; OpenAlex author ID A5025830456, A5079908963. Sources: OpenAlex.

Their work

Papers
43 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
129
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 3 papers · 2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 4 papers · 2019: 6 papers · 2020: 5 papers · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 43

  1. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  2. Plasma cell-free DNA methylome as early detection and prognostic marker for pancreatic cancer Co-author DOI 10.1101/2025.05.29.25328569↗
  3. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations Co-author DOI 10.1101/2025.08.15.670565↗
  4. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  5. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation. Co-author DOI 10.1007/s00330-021-08314-w↗
  6. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.860767↗
  7. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  8. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
  9. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
  10. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  11. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  12. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  13. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  14. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  15. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  16. Trajectories of physical activity, from young adulthood to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canad… Co-author DOI 10.1186/s12885-020-6627-8↗
  17. Trajectories of body mass index, from adolescence to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canada. Co-author DOI 10.1007/s10552-019-01197-9↗
  18. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  19. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  20. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/cci.18.00102↗
  21. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. Co-author DOI 10.1371/journal.pgen.1008344↗
  22. Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases. Co-author DOI 10.18632/oncotarget.26620↗
  23. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Co-author DOI 10.1007/s10897-018-0212-1↗
  24. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  25. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗
  26. Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research R… Co-author DOI 10.1200/po.17.00098↗
  27. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Co-author DOI 10.1038/bjc.2017.19↗
  28. BRM polymorphisms, pancreatic cancer risk and survival. Co-author DOI 10.1002/ijc.30369↗
  29. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.030↗
  30. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Co-author DOI 10.1038/nature19823↗
  31. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. First author DOI 10.1038/bjc.2015.220↗
  32. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Co-author DOI 10.1053/j.gastro.2014.11.042↗
  33. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. First author DOI 10.1200/jco.2014.59.7401↗
  34. The association of family history of cancer and medical history with pancreatic cancer risk. Co-author DOI 10.1097/mpa.0000000000000126↗
  35. Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk. Co-author DOI 10.1002/mc.22037↗
  36. Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/aje/kwt052↗
  37. Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. Co-author DOI 10.1186/1479-7364-7-11↗
  38. Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention. Co-author DOI 10.1002/pon.2026↗
  39. Identification of germline genomic copy number variation in familial pancreatic cancer. Co-author DOI 10.1007/s00439-012-1183-1↗
  40. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. First author DOI 10.1007/s11605-011-1781-6↗
  41. Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk. Co-author DOI 10.1093/carcin/bgs028↗
  42. Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk Co-author DOI 10.1093/carcin/bgs169↗
  43. Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment. Co-author DOI 10.1503/cjs.026409↗

Closest collaborators

The 25 strongest of 129 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 39 shared papers, 2012–2026 · strength 3.12
  2. Robert C. Grant · 19 shared papers, 2012–2026 · strength 1.68
  3. George Zogopoulos · 17 shared papers, 2012–2025 · strength 1.34
  4. Grainne Mary O'Kane · 11 shared papers, 2019–2026 · strength 1.21
  5. Spring Holter · 16 shared papers, 2012–2026 · strength 1.19
  6. Jennifer Jane Knox · 11 shared papers, 2018–2026 · strength 1.18
  7. Faiyaz Notta · 9 shared papers, 2016–2026 · strength 0.94
  8. Michelle Chan‐Seng‐Yue · 8 shared papers, 2016–2026 · strength 0.80
  9. Yifan Wang · 7 shared papers, 2019–2025 · strength 0.73
  10. Sandra Elisabeth Fischer · 8 shared papers, 2019–2022 · strength 0.68
  11. Sean Patrick Cleary · 10 shared papers, 2012–2020 · strength 0.58
  12. Gloria M. Petersen · 9 shared papers, 2012–2021 · strength 0.53
  13. Eugenia Flores Figueroa · 4 shared papers, 2020–2026 · strength 0.50
  14. Barbara T. Grünwald · 3 shared papers, 2022–2025 · strength 0.45
  15. Ashton Anthony Connor · 8 shared papers, 2015–2020 · strength 0.44
  16. Michelle Cotterchio · 7 shared papers, 2012–2020 · strength 0.41
  17. Alison P. Klein · 5 shared papers, 2012–2021 · strength 0.38
  18. Yuanchang Fang · 2 shared papers, 2025–2026 · strength 0.36
  19. Erica S. Tsang · 2 shared papers, 2025–2026 · strength 0.36
  20. Hartland Warren Jackson · 2 shared papers, 2025–2026 · strength 0.35
  21. Rayjean J. Hung RJ · 3 shared papers, 2014–2025 · strength 0.34
  22. Masoom A. Haider · 3 shared papers, 2012–2025 · strength 0.33
  23. David F. Schaeffer · 4 shared papers, 2020–2021 · strength 0.33
  24. Daniel John Renouf · 4 shared papers, 2020–2021 · strength 0.33
  25. David Arthur Tuveson · 3 shared papers, 2020–2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.